Search Results
Your search for ,tWo matches 12459 pages
Showing 12101 - 12150Wider Surgical Margins Do Not Appear To Reduce Local Recurrence Rates in Triple-Negative Breast Cancer
Wider surgical margins did not reduce the rate of local recurrence in women with triple-negative breast cancer treated with breast-conserving therapy, according to the results of a study published in the Annals of Surgical Oncology. Pilewskie et al reported that their data support the definition of ...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
Sustained Complete Responses With Novel Immunotherapy in Lymphoma
Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
U.S. Cancer Death Rates Continue Decline, Annual Report Shows
Maintaining a 2 decade–long trend, the cancer death rate in the United States continues to decline, according to the Annual Report to the Nation on the Status of Cancer, published online this week in Cancer. The report, which covers the years 2001 to 2010, shows drops in death rates for a...
No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Protective Effect of Aspirin for Colorectal Cancer Is Associated With rs6983267 T Allele
It has been posited that aspirin treatment may reduce risk for colorectal cancer through inhibition of WNT/cadherin-associated protein β1 (CTNNB1, or β-catenin) signaling. In a study reported in the Journal of the National Cancer Institute, Nan et al investigated the potential role of the ...
Second-Line Therapies May Benefit Patients With Castration-Resistant Prostate Cancer and Poor Performance Status
Patients with castration-resistant prostate cancer and a poor performance status who were previously treated with docetaxel may benefit from currently available second-line therapies, according to the findings of a meta-analysis by Iacovelli et al published in Prostate Cancer and Prostatic...
Final Overall Survival Analysis of CONFIRM Trial Shows Advantage of Higher Dose of Fulvestrant in Advanced Breast Cancer
As reported in the Journal of the National Cancer Institute by Di Leo et al, the final overall survival analysis of the CONFIRM trial has shown a significant benefit of fulvestrant (Faslodex) at 500 mg vs 250 mg in postmenopausal women with locally advanced or metastatic estrogen...
Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas
A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular...
No Benefit of Calcium/Magnesium in Preventing Oxaliplatin-Induced Sensory Neurotoxicity in Patients With Colon Cancer
In a phase III N08CB/Alliance trial reported in the Journal of Clinical Oncology, Loprinzi et al assessed whether calcium and magnesium treatment reduced oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). They found ...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Adjuvant Bisphosphonates Improve Breast Cancer Survival, Reduce Bone Recurrence in Postmenopausal Women With Early Disease
Adjuvant use of bisphosphonates reduced the risk of bone recurrence by 34% and the risk of breast cancer death by 17% in postmenopausal women with early breast cancer in a large meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The potentially...
Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer
There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...
Increased Cardiovascular Risk Despite Healthier Lifestyle Characteristics in Hematopoietic Cell Transplant Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al compared cardiovascular risk and risk factors in hematopoietic cell transplantation recipients with those in a matched general population sample. Hematopoietic cell transplantation survivors were at greater risk for cardiomyopathy, ...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
Idelalisib Achieves High Response Rates in 'Double-Refractory' Indolent NHL
In patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to both rituximab (Rituxan) and an alkylating agent, monotherapy with the selective oral PI3K-delta inhibitor idelalisib produced a high response rate, with responses persisting for 1 year in the average patient, according to...
Continuous Lenalidomide/Low-Dose Dexamethasone Improves Survival vs Standard Treatment in Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using continuous treatment with the doublet of lenalidomide (Revlimid) and low-dose dexamethasone was superior to standard triplet treatment with melphalan, prednisone, and thalidomide (Thalomid) for 72 weeks, according to initial results of...
Gemtuzumab Ozogamicin Reduces Relapse, Improves Event-Free Survival in Pediatric AML
The monoclonal antibody gemtuzumab ozogamicin (Mylotarg) improved event-free survival and reduced the risk of relapse in children with acute myeloid leukemia (AML) in a study from the Children’s Oncology Group, presented at the 55th American Society of Hematology (ASH) Annual Meeting and...
Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies
Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...
Graft Manipulation Improves HLA-Haploidentical Hematopoietic Stem Cell Transplant Outcomes
T-cell–depleted HLA-haploidentical hematopoietic stem cell transplantation can be made more efficacious and safer through the removal of alpha/beta-positive T cells and CD19-positive B cells from the graft, an approach pioneered by Italian investigators who reported results at the 55th...
Higher Levels of HSET Linked to More Aggressive Breast Cancers and Worse Outcomes in African American Women
Data from a study by Ritu Aneja, PhD, Associate Professor in the Department of Biology at Georgia State University in Atlanta, and colleagues indicate that overexpression of the protein HSET is a valuable prognostic biomarker in African American women with breast cancer, but not in Caucasian...
Grade 3 Endometrioid Carcinoma With PIK3CA Mutation Linked to Unfavorable Outcome
The presence of PIK3CA missense mutation appears to be associated with shorter disease-specific survival in grade 3 endometrioid but not serous endometrial carcinoma, according to a study in Gynecologic Oncology. Although McIntyre et al found this type of mutation across all histologic types of...
Genetic Mutation May Play a Role in Worse Outcomes for Obese Prostate Cancer Patients
A study by researchers from Harvard School of Public Health, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital has found that overweight or obese men with prostate cancer whose tumors were positive for the TMPRSS2:ERG genetic mutation had more than a 50% increased risk of dying...
Eight-Gene Profile Predicts Benefit of Adjuvant Trastuzumab in HER2-Negative Disease
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial suggested that efficacy of adjuvant trastuzumab (Herceptin) extended to patients with HER2-negative breast cancer. In a study reported in the Journal of the National Cancer Institute, Pogue-Geile et al identified and...
Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma
A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...
Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy for Gastric Cancers
Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials...
Low-Fat Diet and Fish Oil Supplementation Reduces Cell-Cycle Progression in Prostate Cancer
In a post hoc analysis reported in the journal Cancer Prevention Research, Galet et al analyzed the effects of diet on men with prostate cancer. They found that men who were on a low-fat diet and fish oil supplementation had lower cell-cycle progression scores, which are associated with less...
Thyroid Ultrasound Strategy Identifies Low-Risk Patients Who Can Defer Biopsy
In a study reported in JAMA Internal Medicine, Smith-Bindman et al evaluated the ability of ultrasound imaging characteristics to determine risk of thyroid cancer associated with thyroid nodules. They found that a strategy of using two abnormal nodule characteristics as an indication for biopsy...
Estrogen Levels Affect the Efficacy of PARP Inhibitors in PTEN-Deficient Endometrial Tumors
PARP inhibition appears to be an effective way to shrink PTEN-deficient endometrial tumors with low levels of estrogen but is ineffective in those with high levels of estrogen, according to preclinical study results reported by Janzen et al in Molecular Cancer Therapeutics. The findings suggest...
Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women
A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...
FDA Grants Regular Approval to Crizotinib for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) today granted regular approval for crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Today’s...
Studies Reveal Multiple Gene Alterations Responsible for Drug Resistance in BRAF-Mutated Melanoma
Two studies using whole-exome sequencing of treatment-resistant BRAF-mutated melanomas have identified multiple gene alterations, mostly affecting the MAPK pathway. Molecularly profiling BRAF-mutated melanoma patients at the time of resistance may improve their care by tailoring combinations of...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer
In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...
New Studies Provide Insight Into Melanoma Drug Resistance Pathways and Strategy for Obtaining Durable Responses
Approximately 50% of metastatic melanomas harbor the BRAF mutation, and although most of these melanomas respond dramatically to treatment with BRAF inhibitors, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), nearly all develop resistance to the drugs within 7 to 8 months. While previous...
Targeted Intraoperative Radiotherapy Concurrent With Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Local Breast Cancer Recurrence
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in...
No Advantage of Concurrent vs Sequential Trastuzumab/Anthracycline Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
In the phase III Z1041 trial reported in The Lancet Oncology, Aman U. Buzdar, MD, of The University of Texas MD Anderson Cancer Center, and colleagues compared neoadjuvant therapy with FEC-75 (fluorouracil [5-FU], epirubicin, and cyclophosphamide) followed by paclitaxel plus trastuzumab (Herceptin) ...
Prognostic Model Predicts Metastatic Castration-Resistant Prostate Cancer Survival in Second-Line Chemotherapy After Docetaxel
In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...
Additional Interim Data for Lambrolizumab Show Survival Benefit for Patients With Advanced Melanoma
Additional data for the investigational anti–PD-1 immunotherapy lambrolizumab (MK-3475) were presented yesterday at the 10th International Congress of the Society for Melanoma Research in Philadelphia. In patients with advanced melanoma, lambrolizumab demonstrated an estimated 1-year overall...
Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...
Most Patients Experience Nocturnal Care Disturbances Following Hematopoietic Stem Cell Transplantation
In a study reported in the Clinical Journal of Oncology Nursing, Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois College of Nursing, and colleagues attempted to identify and quantify nocturnal care disruptions in patients undergoing hematopoietic stem cell transplantation. They ...
International Ki67 Reproducibility Study Shows High Intralaboratory but Only Moderate Interlaboratory Reproducibility
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
Intraoperative Radiotherapy Inferior to External Radiotherapy in Preventing Local Recurrence in Early Breast Cancer
A single session of intraoperative radiotherapy with electrons permits delivery of a radiotherapy dose equivalent to that of conventional postoperative whole-breast irradiation. In the ELIOT trial reported in The Lancet Oncology, Umberto Veronesi, MD, of the European Institute of Oncology, and...
Dasatinib Plus Docetaxel Does Not Improve Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...
